Coinbase
COIN
Meta Platforms
META
Amazon
AMZN
MicroStrategy
MSTR
Apple
AAPL
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals International
- 21.120
- -0.730-3.34%
Trading Dec 3 13:08 ET
1.52BMarket Cap-176000P/E (TTM)
21.730High21.100Low99.04KVolume21.680Open21.850Pre Close2.12MTurnover0.59%Turnover Ratio105.60P/E (Static)72.20MShares28.15052wk High3.49P/B356.06MFloat Cap16.56052wk Low--Dividend TTM16.86MShs Float32.880Historical High--Div YieldTTM2.88%Amplitude5.010Historical Low21.370Avg Price1Lot Size
About Kiniksa Pharmaceuticals International Company
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Company Profile
SymbolKNSA
Company NameKiniksa Pharmaceuticals International
Listing DateMay 24, 2018
Issue Price18.00
Founded2024
CEOMr. Sanj K. Patel
MarketNASDAQ
Employees297
Fiscal Year Ends12-31
Address23 Old Bond Street,3rd Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 4PZ
Phone44-781-431-9100
Websitehttps://www.kiniksa.com
Company Executives
- Name
- Position
- Salary
- Sanj K. Patel
- Chief Executive Officer and Chairman of the Board
- 5.30M
- John F. Paolini, M.D.,PhD
- Senior Vice President and Chief Medical Officer
- 1.79M
- Mark Ragosa
- Senior Vice President and Chief Financial Officer
- --
- Eben Tessari
- Senior Vice President and Chief Operating Officer
- 1.75M
- Ross Moat
- Senior Vice President and Chief Commercial Officer
- --
- Michael R. Megna
- Chief Accounting Officer and Group Vice President, Finance
- --
- Cantey Boyd
- Director
- --
- Dr. Stephen R. Biggar,M.D.,PhD
- Independent Director
- 371.96K
- Dr. Richard S. Levy,M.D.
- Independent Director
- 459.75K
- Dr. Felix J. Baker,PhD
- Lead Independent Director
- 411.06K
- Kimberly J. Popovits
- Independent Director
- 362.66K
- Thomas R. Malley
- Independent Director
- 380.36K
- G. Bradley Cole
- Independent Director
- 365.36K
- Tracey L. McCain, Esq.
- Independent Director
- 365.36K
- Dr. Barry D. Quart,Pharm.D.
- Independent Director
- 372.55K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.